-
2024-519706-13-00
6
2026-01-26
Patients with Stable or Unstable coronary syndromes who have undergone
-
2024-518195-31-00
6
2021-09-29
acute myocardial infarction
-
2025-523717-29-00
5
2026-04-28
HFpEF or HFmrEF and obesity
-
2024-516356-18-00
5
2026-02-17
Atherosclerotic cardiovascular disease (ASCVD)
-
2024-516842-21-00
5
2025-01-09
Recurrent ovarian cancer
-
2024-516839-27-00
4
2024-12-09
BRCA wild-type advanced ovarian, fallopian tube and primitive peritone
-
2023-506632-32-00
5
2024-10-28
Metastatic colorectal cancer
-
2024-511959-18-01
5
2024-07-01
Acute Pulmonary Embolism
-
2024-517200-10-00
4
2020-01-31
Advanced non-small-cell lung cancer
-
2024-520399-84-00
6
2025-02-03
Cardiogenic shock
-
2023-506876-28-00
5
2024-08-01
The medical condition we are investigating is type 1 AMI (STEMI and NS
-
2023-509143-27-00
7
2023-11-27
Locally advanced or metastatic solid tumor malignancies, platinum resi
-
2022-501024-20-00
5
2023-07-25
ER+/HER2- Early Breast Cancer
-
2022-501939-16-00
5
2023-05-09
Heart failure (HF) with mildly reduced ejection fraction (HFmrEF) or H
-
2023-506771-10-00
5
2022-03-11
Breast Neoplasm, Neoplasm Metastasis
-
2024-510735-21-00
5
2021-11-26
Atherosclerotic cardiovascular disease (ASCVD)
-
2023-507961-24-00
5
2021-04-19
High-Risk HER2-Positive Breast Cancer
-
2024-518909-18-00
5
2021-03-23
HIV-1 infected individuals currently taking an INSTI-based three-drug
-
2024-513296-41-00
4
2020-12-03
Colorectal cancer spread at distance, RAS BRAF wild type pretreatted
-
2024-511940-20-00
5
2020-02-05
Parkinson's disease
-
2024-514841-12-00
5
2015-10-27
To determine whether the addition of palbociclib to adjuvant endocrine
-
2024-515152-20-00
4
2023-03-02
Stage III and high-risk stage II resected colon cancer patients.
-
2024-514515-10-00
5
2016-06-16
Breast Cancer